These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 37405216)

  • 1. Prognosis of Patients Receiving Chemotherapy for Metastatic Upper Tract Urothelial Carcinoma Compared With Metastatic Urinary Bladder Cancer.
    Adomi S; Fujita K; Kita H; Kuwahara K; Akashi Y; Nishimoto M; Matsumura N; Sugimoto K; Minami T; Nozawa M; Yoshimura K; Tahara H; Hirayama A; Nishioka T; Esa A; Uemura H
    Cancer Diagn Progn; 2023; 3(4):484-490. PubMed ID: 37405216
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The comparison of oncologic outcomes between metastatic upper tract urothelial carcinoma and urothelial carcinoma of the bladder after cisplatin-based chemotherapy.
    Hsieh MC; Chiang PH; Rau KM; Chen YY; Su YL; Huang CH
    Urol Oncol; 2015 Nov; 33(11):495.e9-495.e14. PubMed ID: 26254698
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of cytoreductive surgery for metastatic upper tract urothelial carcinoma: a Surveillance, Epidemiology and End Results (SEER) study of 508 patients.
    Hu H; Lai S; Ni R; Wang M; Lai C; Ji J; Xu T; Hu H
    Transl Androl Urol; 2024 Jun; 13(6):983-993. PubMed ID: 38983475
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Consolidative Radiotherapy for Metastatic Urothelial Bladder Cancer Patients with No Progression and with No More than Five Residual Metastatic Lesions Following First-Line Systemic Therapy: A Retrospective Analysis.
    Aboudaram A; Chaltiel L; Pouessel D; Graff-Cailleaud P; Benziane-Ouaritini N; Sargos P; Schick U; Créhange G; Cohen-Jonathan Moyal E; Chevreau C; Khalifa J
    Cancers (Basel); 2023 Feb; 15(4):. PubMed ID: 36831503
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic Significance of Organ-Specific Metastases in Patients with Metastatic Upper Tract Urothelial Carcinoma.
    Tufano A; Cordua N; Nardone V; Ranavolo R; Flammia RS; D'Antonio F; Borea F; Anceschi U; Leonardo C; Morrione A; Giordano A
    J Clin Med; 2022 Sep; 11(18):. PubMed ID: 36142956
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of surgery on primary site in metastatic upper urinary tract urothelial carcinoma and a nomogram for predicting the survival of patients with metastatic upper urinary tract urothelial carcinoma.
    Zhang X; Wang P; Qi K; Qiao Q; Jiang Y
    Cancer Med; 2021 Nov; 10(22):8079-8090. PubMed ID: 34647688
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Survival Impact of Nephroureterectomy for De Novo Stage IV Nonmetastatic and Metastatic Upper Tract Urothelial Carcinoma.
    Lin WY; Lin MH; Yang YH; Chen WC; Huang CE; Chen MF; Wu CT
    Front Surg; 2022; 9():903123. PubMed ID: 35693310
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical outcomes of immune checkpoint inhibitor plus nab-paclitaxel in metastatic upper tract urothelial carcinoma.
    Su R; Chen Z; Hu H; Jiang S; Chen M; Chen Q; Gellhaus PT; Ornellas AA; Campobasso D; Wei Q; Huang J; Bao Y; Xue W
    Transl Androl Urol; 2023 Sep; 12(9):1416-1425. PubMed ID: 37814696
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adjuvant chemotherapy after radical nephroureterectomy improves the survival outcome of high-risk upper tract urothelial carcinoma patients with cardiovascular comorbidity.
    Luo Y; Feng B; Wei D; Han Y; Li M; Zhao J; Lin Y; Hou Z; Jiang Y
    Sci Rep; 2020 Oct; 10(1):17674. PubMed ID: 33077839
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Personalized peptide vaccination as second-line treatment for metastatic upper tract urothelial carcinoma.
    Suekane S; Ueda K; Nishihara K; Sasada T; Yamashita T; Koga N; Yutani S; Shichijo S; Itoh K; Igawa T; Noguchi M
    Cancer Sci; 2017 Dec; 108(12):2430-2437. PubMed ID: 28940789
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Survival Effect of Chemotherapy in Metastatic Upper Urinary Tract Urothelial Carcinoma.
    Nazzani S; Preisser F; Mazzone E; Marchioni M; Bandini M; Tian Z; Mistretta FA; Shariat SF; Soulières D; Montanari E; Acquati P; Briganti A; Carmignani L; Karakiewicz PI
    Clin Genitourin Cancer; 2019 Feb; 17(1):e97-e103. PubMed ID: 30337106
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Phase II Study of Weekly Docetaxel as Second-Line Chemotherapy in Patients With Metastatic Urothelial Carcinoma.
    Kim YS; Lee SI; Park SH; Park S; Hwang IG; Lee SC; Sun JM; Lee J; Lim HY
    Clin Genitourin Cancer; 2016 Feb; 14(1):76-81. PubMed ID: 26454620
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment patterns, survival, and healthcare utilisation and costs in patients with locally advanced and metastatic bladder cancer in Denmark 2015-2020.
    Nørgaard M; Mailhac A; Fagerlund K; Strunz-McKendry T; Agerbæk M; Jensen JB
    Acta Oncol; 2023 Dec; 62(12):1784-1790. PubMed ID: 37787748
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Survival Effect of Nephroureterectomy in Metastatic Upper Urinary Tract Urothelial Carcinoma.
    Nazzani S; Preisser F; Mazzone E; Marchioni M; Bandini M; Tian Z; Mistretta FA; Shariat SF; Soulières D; Saad F; Montanari E; Luzzago S; Briganti A; Carmignani L; Karakiewicz PI
    Clin Genitourin Cancer; 2019 Jun; 17(3):e602-e611. PubMed ID: 31005472
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic Value of Bladder Involvement in the Outcome of Upper Tract Urothelial Carcinoma.
    Meireles S; Dias N; Martins D; Dias C; Gonçalves M; Silva J; Silva CM; Oliveira PD; Soares P; Lopes JM
    Diagnostics (Basel); 2023 Jan; 13(1):. PubMed ID: 36611446
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic significance of non-muscle-invasive bladder tumor history in patients with upper urinary tract urothelial carcinoma.
    Milojevic B; Djokic M; Sipetic-Grujicic S; Grozdic Milojevic I; Vuksanovic A; Nikic P; Vukovic I; Djordjevic D; Bumbasirevic U; Tulic C
    Urol Oncol; 2013 Nov; 31(8):1615-20. PubMed ID: 22521771
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic models for upper urinary tract urothelial carcinoma patients after radical nephroureterectomy based on a novel systemic immune-inflammation score with machine learning.
    Liu J; Wu P; Lai S; Wang J; Hou H; Zhang Y
    BMC Cancer; 2023 Jun; 23(1):574. PubMed ID: 37349696
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum C-reactive protein: a prognostic factor in metastatic urothelial cancer of the bladder.
    Eggers H; Seidel C; Schrader AJ; Lehmann R; Wegener G; Kuczyk MA; Steffens S
    Med Oncol; 2013 Dec; 30(4):705. PubMed ID: 24005810
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Second-Line Chemotherapy for Metastatic Urothelial Carcinoma: Importance of Lymph Node-Only Metastasis as a Prognostic Factor and Construction of a Prognostic Model.
    Salah S; Lee JL; Rozzi A; Kitamura H; Matsumoto K; Srinivas S; Morales-Barrera R; Carles J; Al-Wardat R; Al-Rabi K; Maakoseh M
    Clin Genitourin Cancer; 2016 Jun; 14(3):255-60. PubMed ID: 26552764
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of Systemic Chemotherapy Plus Radical Nephroureterectomy for Metastatic Upper Tract Urothelial Carcinoma.
    Seisen T; Jindal T; Karabon P; Sood A; Bellmunt J; Rouprêt M; Leow JJ; Vetterlein MW; Sun M; Alanee S; Choueiri TK; Trinh QD; Menon M; Abdollah F
    Eur Urol; 2017 May; 71(5):714-718. PubMed ID: 27912971
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.